Very common displays for benefit-risk are forest plots on effect sizes. Those improve by adding information about rates or proportions and totals. The comparison of multiple treatments is easy with trade-off plots. A basic overview of benefits and risk is nicely show with a value tree. The next challenge is on Markov traces. See the Wonderful Wednesday homepage for more detail.

Wonderful Wednesdays are brought to you by the Visualisation SIG. The Wonderful Wednesday team includes Bodo Kirsch, Zachary Skrivanek, Lorenz Uhlmann, Steve Mallett, Rhys Warham, Mark Baillie, Paolo Eusebi, Martin Brown, Benjamin Lang, Lovemore 

Hosted by Emma Crawford, Katie Gwinnell, Alistair Haston, Tabitha Lennox, Oswald Dallimore, Sarah Crossley

Get an insight into how maths is used to help develop experiments to test lifesaving medicines. This webinar showcases the different roles and pathways into the industry and we hear from a panel of professionals who share their experiences and answer your questions!

It is a real challenge to display adverse event data. There are a lot of different aspects to concentrate on. How this can be approached is presented by Bodo Kirsch. Visualisations are available on the Wonderful Wednesday blog. 
The time course of adverse events can be shown with violin plots. To explore the co-occurrence of events a visually enhanced correlation matrix is helpful. Various ways are presented to effectively combine (stacked) bar charts with induvial patient data display and violin plots to explore subgroup differences. The next challenge is on benefit-risk profiles. See the Wonderful Wednesday homepage for more detail.

Wonderful Wednesdays are brought to you by the Visualisation SIG. The Wonderful Wednesday team includes Bodo Kirsch, Zachary Skrivanek, Lorenz Uhlmann, Steve Mallett, Rhys Warham, Mark Baillie, Paolo Eusebi, Martin Brown, Benjamin Lang

What is the best visualisation? That depends heavily on the purpose. For exploration interactive and animated plot are presented that enhance the understanding of the data. For explanation a static plot is best if it delivers the message on the first glance. The next challenge is on adverse event hierarchy. See the Wonderful Wednesday homepage for more detail.

Wonderful Wednesdays are brought to you by the Visualisation SIG. The Wonderful Wednesday team includes Bodo Kirsch, Zachary Skrivanek, Lorenz Uhlmann, Steve Mallett, Rhys Warham, Mark Baillie, Paolo Eusebi, Martin Brown, Benjamin Lang

Papers for discussion:

Andrew Grieve: Probability of success and group sequential designs - https://onlinelibrary.wiley.com/doi/10.1002/pst.2346

Zhiwei Zhang, Carrie Nielson, Ching-Yi Chuo & Zhishen Ye: Information-based group sequential design for post-market safety monitoring of medical products using real world data - https://onlinelibrary.wiley.com/doi/10.1002/pst.2385

First some plots are shown to explore the data. Showing the individual data helps to avoid misinterpretations. For the actual comparison of the measurements the Bland-Altman plots are suited best. Further data exploration is supported by adding interactive highlighting to this and other plots. The next challenge is to find the best healthcare related visualisation of 2024. See the Wonderful Wednesday homepage for more detail.

Wonderful Wednesdays are brought to you by the Visualisation SIG. The Wonderful Wednesday team includes: Bodo Kirsch, Zachary Skrivanek, Lorenz Uhlmann, Steve Mallett, Rhys Warham, Mark Baillie, Paolo Eusebi, Martin Brown, Benjamin Lang

Emma May, Holly Prescott, Marius Sieverding, Alun Bedding, Steve Mallett

The 7 Habits of Highly Effective People has had a profound impact on millions of people around the world.  The book focuses on cultivating character and refining personality. Its principles are not only transformative for personal growth but also serve as powerful tools for professional development.  Over the past few months, the PSI Book Club has been deeply engaged in exploring these transformative principles. Through small group discussions, members have examined real-world applications, shared personal insights, and unpacked the key lessons embedded in these habits.  In this session, we’ll bring those rich discussions to the forefront. Our focus will be on how these principles can be effectively applied in the professional realm, driving leadership, teamwork, and personal growth. We are excited to welcome two esteemed guests: Alun Bedding, [Executive Coach and Consultant, former Global Head of Statistical Methods Collaboration and Outreach at Roche], and Steve Malett, [Senior Manager Statistics at Veramed]. Both Alun and Steve bring extensive industry experience and have served as facilitators for “The 7 Habits” discussions within the PSI Book Club.  Join us for an insightful conversation on why these habits remain relevant today, how they’ve impacted members of our book club, and how you can apply them in your own life. This is also an excellent opportunity to engage with our panel experts, ask questions, and gain practical advice for your personal and professional journey.

Lea Vaas

The replacement of concurrent control animals by so-called Virtual Control Groups (VCGs) may reduce the use of animals in systemic toxicity studies and contributes to the 3R's principle of animal experimentation. However, the idea of replacing living beings with virtual data from historical data sets has so far not been introduced into the design of regulatory animal studies. Major steps facilitating review of methodology for derivation of ViCoGs from historical control data and performance testing in statistical analysis, are the collection, curation and sharing of suitable sets of historical control data from preclinical toxicity studies. This talk will summarize accomplished and ongoing efforts for cross-industry provision of data resources, standardization and curation activities and line out both general ideas and specific methodology for derivation of ViCoGs. Moreover, a discussion of advantages, pitfalls, real-world examples, potential solutions is given and ideas for transferring these insights into regulations and guidelines are presented.

Professor Nick Andrews

With an increasing number of vaccines recommended in pregnancy it is important to consider how best to evaluate safety. There are particular challenges in assessing safety in pregnancy such as healthy vaccinee effects, immortal time bias and biases introduced in the days close to birth. In this talk I will discuss these challenges and consider different designs with pros and cons, this will include presenting a study I have done using a nested case -control study within a cohort for Covid-19 vaccine safety and plans for a target trial emulation approach for assessing RSV vaccine in pregnancy.

Sanne Roels, Tim Morris, Kelly van Lancker (hosts) Kaspar Rufibach (Merck), Susan Gruber (TL revolution) and Florian Lasch (EMA)

First, Kaspar Rufibach (Merck) shared his perspectives on opportunities to apply causal methods. Next, Susan Gruber (TL revolution) discussed targeted learning as a framework to address causal questions and the importance of sensitivity analyses. Finally, Florian Lasch (EMA) discussed both the importance of the causal inference angle in determining estimands, and will discuss a case study.  The webinar ended with a panel discussion. 

Several design choices must be made while creating a visualisation. Bar chart or line plot? Faceted plots or overplotting? Should there be used multiple colours? And if yes, what colour scheme is best? How to optimize axes, legend, background and title? See the step-by-step improvement. The next challenge will be about intra- and interrater reliability. See the Wonderful Wednesday homepage for more detail.

Wonderful Wednesdays are brought to you by the Visualisation SIG. The Wonderful Wednesday team includes: Bodo Kirsch, Zachary Skrivanek, Lorenz Uhlmann, Steve Mallett, Rhys Warham, Mark Baillie, Paolo Eusebi, Martin Brown, Benjamin Lang

Margaret Gamalo, Cordula Zeller, Patrick Schlömer, Dali Zhou

This webinar discusses the complexities and opportunities of clinical trials with hierarchical composite endpoints, covering topics such as win odds, win ratio, net benefit as well as regulatory considerations when defining hierarchical composite endpoints. This webinar starts with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations are illustrated through case studies from clinical trials in heart failure and chronic kidney disease. The webinar concludes with a discussion and a Q&A.